Overview

Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients

Status:
Unknown status
Trial end date:
2012-10-01
Target enrollment:
0
Participant gender:
All
Summary
To assess the safety, tolerability and efficacy of Raltegravir (RAL) when combined with other antiretroviral drugs in treatment-experienced Chinese HIV-infected patients, including those with multi-drug resistant HIV-1 infection or drug intolerance.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shanghai Public Health Clinical Center
Treatments:
Raltegravir Potassium
Criteria
Inclusion Criteria:

- HIV-infected patients aged over 18 who have failed previous antiretroviral treatment
with multi-drug resistant or with multi-drug intolerance

Exclusion Criteria:

- The patient is aged below 18 or over 65 years

- The patient has serious opportunistic infections or tumors